Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Shepherd

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II TrialR L Burkes, R J Ginsberg, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2011
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trialsT Reiman, R Lai, A S Veillard, et al.
Current Oncology (Toronto, Ont.)|January 5, 2019
Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohortR A Juergens, C Mariano, J Jolivet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1996
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II studyU Gatzemeier, F A Shepherd, T Le Chevalier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trialsP Wheatley-Price, F Blackhall, S-M Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 1997
Induction treatment for resectable non-small-cell lung cancerM C Perry, J Deslauriers, K S Albain, et al.
Journal of the National Cancer Institute|December 10, 1997
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working CadreM A Tucker, N Murray, E G Shaw, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2006
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancerNatasha B Leighl, G D Goss, P G Lopez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerC Lim, M S Tsao, L W Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24R Goodwin, K Ding, L Seymour, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II TrialR L Burkes, R J Ginsberg, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2011
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trialsT Reiman, R Lai, A S Veillard, et al.
Current Oncology (Toronto, Ont.)|January 5, 2019
Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohortR A Juergens, C Mariano, J Jolivet, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1996
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II studyU Gatzemeier, F A Shepherd, T Le Chevalier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trialsP Wheatley-Price, F Blackhall, S-M Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 1997
Induction treatment for resectable non-small-cell lung cancerM C Perry, J Deslauriers, K S Albain, et al.
Journal of the National Cancer Institute|December 10, 1997
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working CadreM A Tucker, N Murray, E G Shaw, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2006
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancerNatasha B Leighl, G D Goss, P G Lopez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerC Lim, M S Tsao, L W Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24R Goodwin, K Ding, L Seymour, et al.
Pageof 18